ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes

Table 4 Previous studies

Reference	N° of Pts	Tumor Stage	Response rate
Brausi M et al., Urology 1998 [20]	13	Ta-T1 Marker lesion	40% (at 6 months)
Di Stasi MS et al., J Urol 2003 [21]	108	BCG-naïve multifocal Cis	52.8% (at 6 months)
Sockett L et al., BJUInt 2008 [36]	13	BCG-refractory HGNMIBC	31% (at 15 months)
Riedl CR et al., J Urol 1998 [39]	16	Ta-T1	56% (at 14.1 months)
Our experience	23	BCG-refractory HGNMIBC	61.5% (at 36 months)

ISSN: 1471-2407